A disappointing June for Alzheimer's disease, with setbacks for several products

Retrieved on: 2022-06-28 16:33:39

Tags for this article:

Drugs

Monoclonal antibodies

Treatment of Alzheimer's disease

Life Sciences

Health sciences

5-HT2A antagonists

Atypical antipsychotics

Biogen

Spinal muscular atrophy

Aducanumab

Brexpiprazole

Donanemab

Click the tags to see associated articles and topics

A disappointing June for Alzheimer's disease, with setbacks for several products. View article details on HISWAI: https://www.clinicaltrialsarena.com/comment/june-alzheimers-disease/

Excerpt

This June, however, has been a disappointing month for the AD space with several companies, including Roche, Athira, Acadia and Biogen, announcing ...

Article found on: www.clinicaltrialsarena.com

View Original Article